Clinical trial
A Phase 2 Double-blind, Placebo-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Adjunctive and Monotherapy Treatment of Participants With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
NCT04969510 is registered in ClinicalTrials.gov with Praxis Precision Medicines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-blind, Placebo-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Adjunctive and Monotherapy Treatment of Participants With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- Lead sponsor
- Praxis Precision Medicines
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 24, 2021
- Completion date
- August 2, 2022
- Enrollment
- 110 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.